Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis.
Miquel Bioque, Sergi Mas, M. Costanzo, Bibiana Cabrera, A. Lobo, Ana González-Pinto, E. Rodríguez-Toscano, Iluminada Corripio, Eduard Vieta, Immaculada Baeza, Á. Ibáñez, M. Fraile, Manuel J Cuesta, Gisela Mezquida, A. Lafuente, Miquel Bernardo
European Neuropsychopharmacology June 1, 2019 DOI: 10.1016/j.euroneuro.2019.04.005 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 562 |
| Population | 321 patients with a first episode of psychosis and 241 matched healthy controls |
| Topics | Cannabis |
| Key findings | Carriers of the T allele of the FAAH rs2295633 SNP who used cannabis had a tenfold higher odds of a first episode of psychosis compared to cannabis users without this genotype. |
Abstract
Alterations of the endocannabinoid system (ECS) may play an important role in the development of schizophrenia and other psychotic disorders. Cannabis use is one of the environmental factors more repeatedly related to an increase the risk of developing a psychotic episode, while its use modifies the ECS normal function. In the present study we purposed to examine the gene by environment (GxE) interaction between 15 selected single nucleotide polymorphisms (SNPs) related to the ECS and cannabis use in a cohort of 321 patients with a first episode of psychosis (FEP) and 241 matched healthy controls. We found the fatty-acid amide hydrolase (FAAH) rs2295633 SNP genetic polymorphism was associated with a greater risk of presenting a FEP in subjects with relevant cannabis use, but not in subjects without a history of cannabis use. The probability of presenting a FEP was tenfold higher (OR: 10.69) in cannabis users who were homozygote carriers of the T allele of the FAAH rs2295633 SNP, compared to users of cannabis without this genotype. We also found that a higher a proportion of TT carriers of the FAAH rs2295633 SNP with a positive history of cannabis use was treated with high potency antipsychotic. This study has identified a GxE-environment interaction between a genetic polymorphism from the ECS and cannabis use involved in the risk of presenting a FEP. Although this preliminary data should be replicated with independent samples, our results highlight the importance of the pro-psychotic effects of exogenous cannabis use over the ECS in certain subjects.
Comparable studies
Other observational and cohort studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| High-potency cannabis and the risk of psychosis People with first episode of psychosis and healthy controls from the local population | 2009 | Case-control study | n = 454 |
| Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population | 2013 | Observational study | |
| Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people | 2000 | Observational | |
| Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study Individuals from the general population in Germany aged 14-24 at baseline | 2011 | Observational cohort | n = 1,923 |
| Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases Patients treated for cannabis-induced psychotic symptoms in Denmark between 1994 and... | 2005 | Observational cohort | n = 535 |
Citations in the library
Cited by 8
- Exploration of cannabis use and polygenic risk scores on the psychotic symptom progression of a FEP cohort Psychiatry Research May 8, 2023
- Cannabis Use and Endocannabinoid Receptor Genes: A Pilot Study on Their Interaction on Brain Activity in First-Episode Psychosis International Journal of Molecular Sciences April 19, 2023
- Sustratos genéticos de la psicosis asociada al cannabis Revista Española de Drogodependencias December 30, 2022
- Genetic substrates of cannabis-associated psychosis Revista Española de Drogodependencias December 30, 2022
- Clinical and cognitive outcomes in first-episode psychosis: focus on the interplay between cannabis use and genetic variability in endocannabinoid receptors Frontiers in Psychology August 12, 2024
and 3 more in the library